iSelect Fund
  • Portfolio
  • Team
  • Focus Areas
    • Food & Agriculture
    • Healthcare
    • Food is Health
    • Soil Health
    • Impact Investing
    • Entrepreneurs
  • Invest
  • Insights
  • Contact
  • My iSelect
    • My iSelect Login
Select Page

St. Louis funding group surpasses $100M in startup investment

Read more

Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors

Read more

University of Oklahoma Biomedical Engineering Professor Conducts Study to Develop Booster with Potential to Improve Eventual COVID-19 Vaccine

Read more

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors

Read more
2 Companies That Are Working to Cure Cancer Right Now

2 Companies That Are Working to Cure Cancer Right Now

In 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people died as a result of the disease, according to the National Cancer Institute. These numbers are staggering. The challenge for clinicians and researchers is... Read more

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors

Read more
« Older Entries

Related Posts

  • Infrastructure Investing
    The $3 Trillion Problem: America's Infrastructure Crisis
  • Obesity Treatment
    Gila Therapeutics Completes Phase I Clinical Trial
  • Immunophotonics
    Immunophotonics, SAKK Move Forward with Research Collaboration
  • Neuros Medical Nerve Block Technology
    iSelect Portfolio: Neuros Medical Closes $20 Million Funding Round
AgTechFund BLOG SIDEBAR

(314) 219-8688

7750 Maryland Ave
Box 11826
St. Louis, MO 63105

Crunchbase   Twitter   LinkedIn   Facebook   YouTube

Securities offered through North Capital Private Securities ("NCPS"), Member FINRA/SIPC, located at 623 East Ft. Union Blvd, Suite 101, Salt Lake City, UT 84047. NCPS does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.  Please review North Capital’s Form CRS and its background on FINRA’s BrokerCheck.  Investments in private offerings are speculative, illiquid and involve a high degree of risk and those investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results.  All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.